Difelikefalin
1024828-77-0
SHENZHEN
Hybio
/
2026-02-28
Peptide,Polypeptides
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceDifelikefalin has been used in trials studying the treatment of Acute Pain and Postoperative Pain.
Difelikefalin, a novel drug discovered by Cara Therapeutics and developed by Vifor Pharma, was approved by the USFDA and the European Medicines Agency (EMA) in 2021 for the treatment of moderate to severe pruritus (pruritus). It is a highly selective κ-type opioid receptor agonist administered as an intravenous injection. difelikefalin restricts its action to the peripheral nervous system, which reduces central nervous system side effects such as sedation, anxiety and hallucinations. This peripheral restriction makes difelikefalin potentially advantageous in the treatment of pruritus, especially in patients who experience refractory pruritus due to renal failure or other conditions.Basic Info-
Product Name:
Difelikefalin
Other Name:Difelikefalin (CR845);Difelikefalin(CR-845, FE-202845);CKD-943;CKD-943; CR 845; FE 202845; KORSUVA; MR13A9;DIFELIKEFALIN;CR845;CR 845;FE 202845;KORSUVA;MR13A9
CAS No.:1024828-77-0
Molecular Formula:C36H53N7O6
InChIKeys:FWMNVWWHGCHHJJ-SKKKGAJSSA-N
Molecular Weight:679.85
Exact Mass:679.40573244
UNII:NA1U919MRO
Color/Form:White to off-white
Categories:
Characteristics-
Density:
1.214±0.06 g/cm3(Predicted)
Boiling Point:1005.5±65.0 °C(Predicted)
PKA:2.05±0.20(Predicted)
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Peptide,Polypeptides
-
Location:
No.9, Linkong West Street, Hengdian Street, Huangpi District Wuhan, Hubei, China
-
Total Employees:
Above 1000
-
Year of Establishment:
2014
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product